American Journal of Cardiology
Volume 102, Issue 9, Supplement , Pages 18J-23J , 3 November 2008

Safety and Efficacy Update on First-Generation Drug-Eluting Stents

  • Christian Spaulding, MD

      Affiliations

    • Corresponding Author InformationAddress for reprints: Christian Spaulding, MD, Cardiology Department, Cochin Hospital, René Descartes University, 27 Rue du Fg St. Jacques, 75014, Paris France

References 

  1. Serruys PW, Ong ATL, van Herwerden LA, Sousa J, Jatene A, Bonnier J, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575–581
  2. Weaver WD, Reisman MA, Griffin JJ, Butler C, Leimgruber P, Henry T, et al. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomized trial. Lancet. 2000;355:2199–2203
  3. Stone GW, Ellis SG, Colombo A, Dawkins KD, Grube E, Cutlip DE, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare-metal stent implantation. Circulation. 2007;115:2842–2847
  4. Schühlen H, Kastrati A, Mehilli J, Hausleiter J, Pache J, Dirschinger J, et al. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J. 2004;147:317–322
  5. Van Belle E, Ketelers R, Bauters C, Périé M, Abolmaali K, Richard F, et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation. 2001;103:1218–1224
  6. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  7. Stettler C, Wandel S, Allemann S, Kastrati A, Morice M, Schömig A, et al Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937–948
  8. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667–678
  9. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–1039
  10. Mauri L, Hsieh W, Massaro JM, Ho KKL, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–1029
  11. Schömig A, Dibra A, Windecker S, Mehilli J, Suárez de Lezo J, Kaiser C, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1373–1380
  12. James S, Carlsson J, Lindback J, Nilsson T, Stenestrand U, Wallentin L, et al. Long term outcomes with drug-eluting stents vs bare-metal stents in Sweden: one additional year of follow up. Slide presentation at European Society of Cardiology Congress 2007; September 2 2007;Vienna, Austria
  13. DEScover Registry: DES outperformed bare metal stents. [TCT 2006 daily press release] http://www.tct2006.com/Dailies_TCT2006/monday_fulltext/DEScover_Registry_DES_Outperformed_Bare_Metal_Stents.htmlAccessed April 9, 2008
  14. Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Baki TT, Gandhi SK, et al. Off-label DES vs BMS treatment: outcomes at 2 years. Presented at the Transcatheter Cardiovascular Therapeutics 19th Annual Scientific Symposium; October 20–25, 2007; Washington, DC. Abstract 408 http://www.aievolution.com/tct0701/index.cfm?do=abs.viewAbs&abs=3592Accessed April 8, 2008
  15. Maeng M, Jensen LO, Kaltoft A, Bøttcher M, Hansen HHT, Krusell LR, et al Stent thrombosis, myocardial infarction, and mortality following drug-eluting and bare metal stent coronary interventions in patients with diabetes mellitus. Presented at the Transcatheter Cardiovascular Therapeutics 19th Annual Scientific Symposium; October 20–25, 2007; Washington, DC. Abstract 66 http://www.aievolution.com/tct0701/index.cfm?do=abs.viewAbs&abs=3259Accessed April 8, 2008
  16. Brodie BR, Stuckey T, Downey W, Humphrey A, Bradshaw B, Metzger C, et al Outcomes and complications with off-label versus on-label use of drug-eluting stents: results from the STENT registry. Presented at the Transcatheter Cardiovascular Therapeutics 19th Annual Scientific Symposium; October 20–25, 2007; Washington, DC. Abstract 106 http://www.aievolution.com/tct0701/index.cfm?do=abs.viewAbs&abs=3299Accessed April 8, 2008

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)01494-X

doi: 10.1016/j.amjcard.2008.09.005

American Journal of Cardiology
Volume 102, Issue 9, Supplement , Pages 18J-23J , 3 November 2008

Article Tools

* Image Usage & Resolution